JPMorgan downgraded Orion to Neutral, citing fair valuation and limited upside amid economic uncertainty. Price target cut to $12; sees 2026 free cash flow yield at 15% after La Porte project wraps up. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.

HOUSTON, April 24, 2025 ( GLOBE NEWSWIRE ) -- APA Corporation ( Nasdaq: APA ) and its partners Lagniappe Alaska, LLC, an Armstrong company, and Oil Search ( Alaska ) , LLC, a subsidiary of Santos Limited, today announced the results of the successful flow testing of the Sockeye-2 exploratory ...

Toast's TOST short percent of float has risen 13.79% since its last report. The company recently reported that it has 26.84 million shares sold short, which is 5.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.43 days to cover their ...

Jay Clayton, recently appointed interim US Attorney for the Southern District of New York ( SDNY ) and former chair of the Securities and Exchange Commission, has begun offering statements in criminal cases involving crypto fraud.In an April 23 notice, the US Attorney's Office said Eugene ...

Key Takeaways:The Bitcoin long-term holder cohort saw a $26 billion value increase as BTC price surged to $94,900.Short-term holders sold at a loss in early April.Bitcoin's 30% correction lines up with historical cycles, and BTC could find support in the $88,750 and $91,000 zone.

Q1 adjusted EPS hit $1.45 vs. $1.23 estimate; revenue reached $698 million vs. $685.84 million expected. 2025 EPS guidance raised to $6.15-$6.35; sales forecast up to $2.98 billion. Don't face extreme market conditions unprepared.

Shares of Cantor Equity Partners have soared ahead of its planned merger to launch a new Bitcoin company called Twenty One.

New York City, April 24, 2025 ( GLOBE NEWSWIRE ) -- Why brain fog, mental fatigue, and memory lapses are becoming increasingly common in today's fast-paced world How Brain Savior by Mindful Wellness offers stimulant-free, plant-based cognitive support

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of ...

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in ...